Considerations for Design and Data Analysis of Noninferiority/Superiority Cardiovascular Trials

By Quan Hui   Li Mingyu   Zhao Peng-Liang   Cho Meehyung   Zhang Ji   Wu Yujun  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 1, 2013-01 ,pp. : 239-260

Taylor & Francis Ltd

Access to resources Recommend Favorite

A Note on Partial Covariate-Adjustment and Design Considerations in Noninferiority Trials When Patient-Level Data are not Available

By Nie Lei   Soon Guoxing (Greg)   Qi Karen   Chen Yong   Chu Haitao  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 1042-1053

Taylor & Francis Ltd

Access to resources Recommend Favorite

A Ratio Test in Active Control Non-Inferiority Trials with a Time-to-Event Endpoint

By Wang Yong-Cheng  

Journal of Biopharmaceutical Statistics, Vol. 16, Iss. 2, 2006-03 ,pp. : 151-164

Taylor & Francis Ltd

Access to resources Recommend Favorite

Nemonoxacin met the primary endpoint of noninferiority versus levofloxacin for community-acquired pneumonia

By  

Inpharma, Vol. 1, Iss. 1634, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Issues with Statistical Risks for Testing Methods in Noninferiority Trial Without a Placebo ARM

By Hung H. M. James  

Journal of Biopharmaceutical Statistics, Vol. 17, Iss. 2, 2007-03 ,pp. : 201-213

Taylor & Francis Ltd

Access to resources Recommend Favorite